- Synthesis of 2-azastilbene derivatives with intramolecular charge transfer
-
The condensation reaction of 2-cyanomethyl-5-nitropyridine with aromatic aldehydes has been carried out with the aim of preparing 2-azastilbene derivatives having intramolecular charge transfer. The yield of the condensation products can be increased if the reaction is carried out in the medium used for obtaining the starting 2-cyanomethyl-5-nitropyridine without separating or purifying it. The electronic absorption spectra of the compounds show a charge-transfer band, the energy of which increases and the intensity falls with lowering of the electron-donor properties of the substituent in the 4-position. Introduction of the heteroatom into the acceptor part when changing from the stilbene to the 2-azastilbene system is accompanied by a decrease in the energy and increase in the intensity of the charge-transfer electronic transition.
- Kokars,Yanishevskii,Kampars
-
-
Read Online
- COMPOUNDS FOR MODULATING IL-17
-
The invention relates generally to compounds and their therapeutic use. More particularly, the invention relates to compounds that modulate the activity of IL-17 and/or are useful in the treatment of medical conditions, such as inflammatory diseases and other IL-17-associated disorders.
- -
-
Paragraph 00191
(2014/05/24)
-
- FUSED HETEROARYLS AND THEIR USES
-
Provided are certain fused heteroaryls, compositions thereof and methods of use therefor.
- -
-
Paragraph 0146; 0148
(2013/07/31)
-
- FUSED HETEROARYLS AND THEIR USES
-
Provided are certain fused heteroaryls, compositions thereof and methods of use therefor.
- -
-
Page/Page column 31
(2012/04/04)
-
- AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR
-
The present invention relates to aromatic compounds of the formula (I) wherein Ar is phenyl or an aromatic 5-or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; E is CR6R7 or NR3;R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated Cl-C4--alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C 4-cycloalkylmethyl, fluorinated C3-C4--alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H, C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1--C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C 3-C4-cycloalkylmethyl, fluorinated C3--C 4-alkenyl, or R1a and R2 together are (CH 2)n with n being 2, 3 or 4, or R1a and R 2a together are (CH2)n with n being 2, 3 or 4; R2 and R2a are independently of each other H, C1-C4-alkyl or fluorinated C1-C 4-alkyl or R2a and R2 together are (CH 2)m with m being 1, 2, 3, 4 or 5; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, fluorine, C1-C4-alkyl and fluorinated C1-C4-alkyl or together form a moiety (CH2)p with p being 2, 3, 4 or 5; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
- -
-
Page/Page column 114-115
(2010/11/08)
-
- Epoxysuccinamide derivative or salt thereof
-
PCT No. PCT/JP98/01778 Sec. 371 Date Dec. 17, 1998 Sec. 102(e) Date Dec. 17, 1998 PCT Filed Apr. 17, 1998 PCT Pub. No. WO98/47887 PCT Pub. Date Oct. 29, 1998The invention relates an epoxysuccinamide derivative represented by a formula (I): wherein R1 represents a hydrogen atom, an alkyl or aminoalkyl group, R2 represents an aminoalkyl group which May be substituted, an aryl group which may be substituted, a heterocyclic group which may be substituted, an aralkyl group which may be substituted, or an alkyl group substituted by a heterocyclic ring which may be substituted, or R1 and R2 may form a nitrogen-containing heterocyclic ring, which may be substituted, together with the adjacent nitrogen atoms, and R3 and R4 are the same or different from each other and independently represent a hydrogen atom, or an alkyl or aralkyl group, or a salt thereof, a preparation process thereof, and a medicine comprising such a derivative or salt as an active ingredient. This compound has a specific inhibitory activity for cathepsin L and family enzymes thereof, and is useful as an agent for preventing and treating metabolic osteopathy such as osteoporosis and hypercalcemia.
- -
-
-
- Synthesis of Some Nitropyridylacetonitriles
-
A new synthesis of nitropyridylacetonitriles 4 has been developed, using tert-butyl cyanoacetate and the corresponding chloropyridines 2.The tert-butyl esters are removed by acid-catalyzed dealkoxycarbonylation.
- Katz, R. B.,Voyle, M.
-
p. 314 - 316
(2007/10/02)
-
